Taysha Gene Therapies is trading 8.47% higher at $4.48 after hours, but its specific driver remains unclear. - The regular-session close was $4.13; no verified new company-specific announcement explaining the October 30 move was found. The investor-relations page lists releases dated October 1 and 2. - A story suggesting a new Astellas investment recycles a 2022 deal and is not a confirmed October 30 catalyst. - The broader market was sharply lower, which does not explain the stock’s opposite-direction move.